ClinicalTrials.gg
CompletedNCT01922271FASTUpdated Jan 1, 2015Results posted

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 4 interventional study of NVA237 and Tiotropium in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in Germany. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
37th of 73
152 · median 152
Started
2013
with 4 others
Phase 4
11 of 73
1 open now
Registered
35th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 37th largest by enrollment, is one of 5 that started in 2013, is one of 11 in phase 4, and was the 35th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and specific airway resistance in patients with moderate to severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults aged ≥40 years
  • Patients with moderate to severe defined by a post-bronchodilator (FEV1)/(FVC) Forced Vital Capacity ratio of \<0.70 and a post-bronchodilator FEV1 of ≤70% and FEV1 ≥ 30% of predicted normal values.
  • Current or ex-smokers who have a smoking history of at least 10 pack years.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Patients who have a laboratory abnormality at run-in
  • Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment ( \<50 ml/min/1,732) or urinary retention. (BPH patients who are stable on treatment can be considered).
  • Patients with any history of asthma
  • Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation
  • Patients receiving medications in the classes listed in the protocol as prohibited.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    NVA237 followed by tiotropium

    Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.

    Drug: NVA237 · Drug: Tiotropium · Drug: Placebo to tiotropium · Drug: Salbutamol

  • Experimental
    Tiotropium followed by NVA237

    Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.

    Drug: Placebo to NVA237 · Drug: Salbutamol

Interventions

  • DrugNVA237

    NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)

  • Tiotropium 18 μg once daily delivered via HandiHaler® device.

  • DrugPlacebo to NVA237

    Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).

  • DrugPlacebo to tiotropium

    Placebo to tiotropium once daily delivered via HandiHaler® device

  • Used as resuce medication

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2

    Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).

    Time frame: Day 1

Secondary outcomes

  1. Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose

    Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.

    Time frame: Day 1

  2. Specific Airway Resistance (sRAW)

    Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa\*s. Whole body plethysmography (Bodybox) is used to measure SRaw.

    Time frame: Day 1

  3. Functional Resistance Capacity (FRCpleth)

    Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).

    Time frame: Day 1

  4. Residual Volume (RV)

    Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).

    Time frame: Day 1

  5. Total Lung Capacity (TLC)

    Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.

    Time frame: Day 1

  6. Inspiratory Capacity (IC)

    Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.

    Time frame: Day 1

07

Results

Posted Jan 1, 2015

Participant flow

PERIOD 1
Participant flow — PERIOD 1
MilestoneNVA237 Followed by TiotropiumTiotropium Followed by NVA237
Started7676
Completed7676
Not completed00
WASHOUT Period
Participant flow — WASHOUT Period
MilestoneNVA237 Followed by TiotropiumTiotropium Followed by NVA237
Started7676
Completed7576
Not completed10
Withdrew: Withdrawal by subject10
PERIOD 2
Participant flow — PERIOD 2
MilestoneNVA237 Followed by TiotropiumTiotropium Followed by NVA237
Started7576
Completed7576
Not completed00

Outcome measures

PrimaryForced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2

Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).

Time frame:
Day 1
Reported as:
Mean · liters per hour
Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2
liters per hourNVA237Tiotropium
Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-21.490 ± 0.42321.453 ± 0.4135
SecondaryForced Expiratory Volume in One Second (FEV1) 15 Min Post Dose

Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.

Time frame:
Day 1
Reported as:
Mean · liters per hour
Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose
liters per hourNVA237Tiotropium
Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose1.433 ± 0.41101.398 ± 0.4092
SecondarySpecific Airway Resistance (sRAW)

Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa\*s. Whole body plethysmography (Bodybox) is used to measure SRaw.

Time frame:
Day 1
Reported as:
Mean · kilopascal (kPa)
Specific Airway Resistance (sRAW)
kilopascal (kPa)NVA237Tiotropium
-45 min (n=152, 150)4.203 ± 1.81024.105 ± 1.8338
30 min (n=150, 151)2.904 ± 1.47593.089 ± 1.4555
1 hr (n=151, 149)2.656 ± 1.30622.877 ± 1.4130
1 hr 30 min (n=151, 150)2.632 ± 1.31522.811 ± 1.4065
2 hr 30 min (n=150, 149)2.643 ± 1.31462.756 ± 1.4091
3 hr 30 min (n=150, 149)2.779 ± 1.44962.828 ± 1.4534
SecondaryFunctional Resistance Capacity (FRCpleth)

Functional Resistance Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).

Time frame:
Day 1
Reported as:
Mean · Liters
Functional Resistance Capacity (FRCpleth)
LitersNVA237Tiotropium
-45 min (n=152, 150)5.211 ± 1.30865.142 ± 1.2656
30 min (n=150, 151)4.823 ± 1.25174.852 ± 1.1812
1 hr (n=151, 149)4.769 ± 1.25714.725 ± 1.1496
1 hr 30 min (n=151, 149)4.756 ± 1.23664.714 ± 1.1523
2 h 30 min (n= 150, 149)4.736 ± 1.15454.676 ± 1.2243
3 h 30 min (n= 150, 148)4.761 ± 1.22864.704 ± 1.1911
SecondaryResidual Volume (RV)

Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).

Time frame:
Day 1
Reported as:
Mean · Liters
Residual Volume (RV)
LitersNVA237Tiotropium
-45 min (n=152, 150)4.433 ± 1.25964.344 ± 1.1707
30 min (n=150, 151)3.996 ± 1.18624.035 ± 1.0689
1 hr (n=151, 149)3.891 ± 1.19973.913 ± 1.0281
1 hr 30 min (n=151, 149)3.910 ± 1.15343.903 ± 1.0281
2 h 30 min (n= 150, 149)3.893 ± 1.04863.861 ± 1.1058
3 h 30 min (n= 150, 148)3.970 ± 1.15763.895 ± 1.0740
SecondaryTotal Lung Capacity (TLC)

Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.

Time frame:
Day 1
Reported as:
Mean · Liters
Total Lung Capacity (TLC)
LitersNVA237Tiotropium
-45 min (n=152, 150)7.380 ± 1.47817.335 ± 1.4328
30 min (n=150, 151)7.255 ± 1.46287.274 ± 1.4032
1hr (n=151, 149)7.224 ± 1.42947.161 ± 1.4015
1hr 30 min (n=151, 149)7.227 ± 1.43837.165 ± 1.3690
2hr 30 min (n=150, 149)7.203 ± 1.37007.149 ± 1.4476
3hr 30 min (n=150, 148)7.240 ± 1.42977.149 ± 1.3963
SecondaryInspiratory Capacity (IC)

Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.

Time frame:
Day 1
Reported as:
Mean · Liters
Inspiratory Capacity (IC)
LitersNVA237Tiotropium
-45 min (n=152, 150)2.169 ± 0.55482.193 ± 0.5583
30 min (n=150, 151)2.433 ± 0.59342.422 ± 0.5996
1hr (n=151, 149)2.455 ± 0.60012.435 ± 0.5908
1hr 30 min (n=151, 150)2.472 ± 0.62002.457 ± 0.5883
2hr 30 min (n=150, 149)2.467 ± 0.59292.474 ± 0.6051
3hr 30 min (n=150, 149)2.479 ± 0.60362.449 ± 0.5907

Adverse events

Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—2/152 (1.3%)8/152 (5.3%)
Tiotropium—2/151 (1.3%)15/151 (9.9%)
Most frequent serious events
Most frequent serious events
EventNVA237Tiotropium
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1521/151
NephrectomySurgical and medical procedures0/1521/151
Acute myocardial infarctionCardiac disorders1/1520/151
Myocardial infarctionCardiac disorders1/1520/151
Most frequent other events
Showing 10 of 14
Most frequent other events
EventNVA237Tiotropium
NasopharyngitisInfections and infestations3/1524/151
CoughRespiratory, thoracic and mediastinal disorders1/1523/151
RhinitisInfections and infestations0/1522/151
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1522/151
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1520/151
ContusionInjury, poisoning and procedural complications0/1521/151
Electrocardiogram QT prolongedInvestigations0/1521/151
Back painMusculoskeletal and connective tissue disorders0/1521/151
HeadacheNervous system disorders1/1521/151
Benign prostatic hyperplasiaReproductive system and breast disorders0/1521/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)NVA237 Followed by TiotropiumTiotropium Followed by NVA237Total
Mean61.9 ± 7.261.7 ± 8.261.8 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)NVA237 Followed by TiotropiumTiotropium Followed by NVA237Total
Female282654
Male485098
08

Study locations

14 sites
  • Novartis Investigative Site
    Berlin, 12043, Germany
  • Novartis Investigative Site
    Berlin, 12203, Germany
  • Novartis Investigative Site
    Berlin, 12687, Germany
  • Novartis Investigative Site
    Berlin, 13086, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Gelsenkirchen, 45879, Germany
  • Novartis Investigative Site
    Grosshansdorf, 22947, Germany
  • Novartis Investigative Site
    Gummersbach, 51643, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Kassel, 34121, Germany
  • Novartis Investigative Site
    Leipzig, 04207, Germany
  • Novartis Investigative Site
    Lübeck, 23552, Germany
  • Novartis Investigative Site
    Rüdersdorf, 15562, Germany
  • Novartis Investigative Site
    Sonneberg, 96515, Germany
09

References and documents

Publications

  • Watz H, Mailander C, May C, Baier M, Kirsten AM. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial. Pulm Pharmacol Ther. 2017 Feb;42:13-20. doi: 10.1016/j.pupt.2016.12.001. Epub 2016 Dec 9. PubMed 27940287 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2013
First posted
Aug 14, 2013
Start
Aug 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Jan 1, 2015
Last update
Jan 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01922271
Responsible party
Sponsor
First posted
Aug 14, 2013
Start date
Aug 2013
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Jan 1, 2015
Last update
Jan 1, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion